Cytotoxic T-Cell Response to the Cancer Testis Antigen PASD1 In Multiple Myeloma: PASD1 Peptides for a Generic Vaccine to Treat PASD1-Positive Haematological Malignancies.

Cytotoxic T-Cell Response to the Cancer Testis Antigen PASD1 In Multiple Myeloma: PASD1 Peptides for a Generic Vaccine to Treat PASD1-Positive Haematological Malignancies.

Detalhes bibliográficos
Main Authors:	Campbell, A, Ait-Tahar, K, Patel, S, Barnardo, M, Liggins, A, Caibes, M, Banham, A, Collins, G, Hatton, C, Pulford, K
Formato:	Conference item
Publicado em:	2010

Registos relacionados

PASD1 is a potential multiple myeloma-associated antigen.
Por: Sahota, S, et al.
Publicado em: (2006)

PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy.
Por: Cooper, C, et al.
Publicado em: (2006)

Cytotoxic T-cell response to the PASD1 protein in patients with diffuse large B-cell lymphoma
Por: Ait-Tahar, K, et al.
Publicado em: (2009)

Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma.
Por: Ait-Tahar, K, et al.
Publicado em: (2009)

DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma.
Por: Joseph-Pietras, D, et al.
Publicado em: (2010)

CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma.
Por: Ait-Tahar, K, et al.
Publicado em: (2011)

CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma
Por: Kamel Ait-Tahar, et al.
Publicado em: (2011-01-01)

EXPRESSION OF CANCER-TESTIS GENES PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 IN PATIENTS WITH MULTIPLE MYELOMA, THEIR INFLUENCE ON OVERALL SURVIVAL AND RELAPSE RATE
Por: A. A. Solodovnik, et al.
Publicado em: (2018-07-01)

eNSMBL-PASD: Spearheading early autism spectrum disorder detection through advanced genomic computational frameworks utilizing ensemble learning models
Por: Ayesha Karim, et al.
Publicado em: (2025-01-01)

A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies
Por: Liggins, A, et al.
Publicado em: (2010)

A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies.
Por: Liggins, A, et al.
Publicado em: (2010)

Sp17 protein expression and major histocompatibility class I and II epitope presentation in diffuse large B cell lymphoma patients
Por: Ait-Tahar, K, et al.
Publicado em: (2017)

A novel diffuse large B-cell lymphoma-associated cancer testis antigen encoding a PAS domain protein.
Por: Liggins, A, et al.
Publicado em: (2004)

Serologic detection of diffuse large B-cell lymphoma-associated antigens.
Por: Liggins, A, et al.
Publicado em: (2004)

Erratum: Serologic detection of diffuse large B-cell lymphoma-associated antigens (International Journal of Cancer (2004) 110 (563-569))
Por: Liggins, A, et al.
Publicado em: (2004)

Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients
Por: Kamel Ait-Tahar, et al.
Publicado em: (2017-01-01)

Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens.
Por: Cooper, C, et al.
Publicado em: (2011)

MORC4, a novel member of the MORC family, is highly expressed in a subset of diffuse large B-cell lymphomas.
Por: Liggins, A, et al.
Publicado em: (2007)

B and CTL responses to the ALK protein in patients with ALK-positive ALCL.
Por: Ait-Tahar, K, et al.
Publicado em: (2006)

WT1 AND MULTIPLE MYELOMA: A POTENTIAL IMMUNOTHERAPEUTIC APPROACH FOR HAEMATOLOGICAL MALIGNANCIES
Por: Ilaria Dulcamare
Publicado em: (2022-12-01)

Identification of Huntingtin Interacting Protein 1 Related (HIP1R) as a Novel Lymphoma Autoantigen Using Antigen Array Profiling
Por: Wong, K, et al.
Publicado em: (2008)

Identification of Huntingtin interacting protein 1 related (HIP1R) as a novel lymphoma autoantigen using antigen array profiling
Por: Wong, K, et al.
Publicado em: (2009)

Cancer-testis antigen MAGE-C1/ CT7 in multiple myeloma: literature review
Por: E. A. Makunina
Publicado em: (2020-12-01)

Haematology : lecture notes /
Por: Hatton, Chris S. R.
Publicado em: (2012)

Immunochemical studies of antigenic lymphoma-associated proteins.
Por: Pulford, K, et al.
Publicado em: (2002)

Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens.
Por: Christopher D O Cooper, et al.
Publicado em: (2011-01-01)

Cancer/Testis Antigen MAGE-C1/CT7: New Target for Multiple Myeloma Therapy
Por: Fabricio de Carvalho, et al.
Publicado em: (2012-01-01)

Therapeutic targeting of FOXP3-positive regulatory T cells using a FOXP3 peptide vaccine WO2008081581.
Por: Banham, A, et al.
Publicado em: (2009)

The future of academic haematology
Por: Hay, D, et al.
Publicado em: (2016)

Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma.
Por: Lawrie, C, et al.
Publicado em: (2008)

Cytotoxic and apoptotic effects of neurokinin-1 receptor (NK1R) antagonist on multiple myeloma cells
Por: Elham Razani, et al.
Publicado em: (2019-12-01)

Cytotoxic and apoptotic effects of neurokinin-1 receptor (NK1R) antagonist on multiple myeloma cells
Por: Elham Razani, et al.
Publicado em: (2019-12-01)

Prominin‐1 expression in the testis/epididymis and fertility
Por: Christine A. Fargeas, et al.
Publicado em: (2023-01-01)

Angiogenesis and lymphangiogenesis in stage 1 germ cell tumours of the testis.
Por: Jones, A, et al.
Publicado em: (2000)

The diagnostic and prognostic value of haematologic parameters in multiple myeloma patients
Por: Fuyan Han, et al.
Publicado em: (2023-12-01)

Evaluation of Ciprofloxacin Cytotoxic Effect in Rat Testis
Por: Arash Khaki, et al.
Publicado em: (2007-06-01)

Identification of lymphoma-associated antigens using SEREX.
Por: Liggins, A, et al.
Publicado em: (2005)

Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells
Por: Djordje Atanackovic, et al.
Publicado em: (2010-05-01)

Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma.
Por: Pulford, K, et al.
Publicado em: (2000)

An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma
Por: Odai Darawshi, et al.
Publicado em: (2022-11-01)